Rani Therapeutics Holdings, Inc.
For the period ended Mar 31, 2026. Filed May 15, 2026.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Mar 31, 2026 · Filed May 15, 2026
RANI$0.56-2.5%Stored close · as of Nov 10, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Condensed Consolidated Statements of Cash Flows
| Three Months Ended March 31, | ||
|---|---|---|
| 2026 | 2025 | |
| Cash flows from operating activities | ||
| Net loss | $(8,015) | $(12,738) |
| Adjustments to reconcile net loss to net cash used in operating activities: | ||
| Stock-based compensation expense | 2,084 | 3,925 |
| Depreciation and amortization | 161 | 251 |
| Non-cash operating lease expense | 477 | 477 |
| Amortization of debt discount and issuance costs | — | 58 |
| Net accretion and amortization of investments in marketable securities | (244) | (150) |
| Changes in operating assets and liabilities: | ||
| Accounts receivable | — | (600) |
| Contract asset | — | 428 |
| Prepaid expenses and other current assets | (87) | 347 |
| Accounts payable | 549 | 161 |
| Accrued expenses and other current liabilities | 763 | 170 |
| Deferred revenue | (1,708) | — |
| Operating lease liabilities | (477) | (478) |
| Net cash used in operating activities | (6,497) | (8,149) |
| Cash flows from investing activities | ||
| Proceeds from maturities of marketable securities | 21,000 | 21,000 |
| Purchases of marketable securities | (23,435) | (2,720) |
| Purchases of property and equipment | (15) | (51) |
| Net cash (used in)/provided by investing activities | (2,450) | 18,229 |
| Cash flows from financing activities | ||
| Proceeds from employee stock purchase plan | — | 42 |
| Tax withholdings paid on behalf of employees for net share settlement | (32) | (23) |
| Repayment of debt | — | (3,750) |
| Exercise of Pre-funded Warrants in connection with the Private Placement, net of issuance costs of ($5) | 5 | — |
| Net cash used in financing activities | (27) | (3,731) |
| Net (decrease)/increase in cash, cash equivalents and restricted cash equivalents | (8,974) | 6,349 |
| Cash, cash equivalents and restricted cash equivalents, beginning of period | 18,818 | 4,262 |
| Cash, cash equivalents and restricted cash equivalents, end of period | $9,844 | $10,611 |
| Supplemental disclosures of non-cash investing and financing activities | ||
| Interest income receivable included in prepaid expenses and other current assets | $71 | $17 |
| Unrealized loss on short-term investments | $(11) | $— |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.